Jade Biosciences, Inc. JBIO
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 69.20% | 119.93% | 184.34% | 184.34% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 112.10% | 85.79% | 76.16% | 76.16% | |
| Operating Income | -112.10% | -85.79% | -76.16% | -76.16% | |
| Income Before Tax | -73.49% | -5.72% | -49.26% | -49.26% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -73.54% | -5.76% | -49.26% | -49.26% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -73.54% | -5.76% | -49.26% | -49.26% | |
| EBIT | -112.10% | -85.79% | -76.16% | -76.16% | |
| EBITDA | -112.08% | -- | -- | -- | |
| EPS Basic | 12.36% | 93.53% | 90.98% | 90.98% | |
| Normalized Basic EPS | -0.04% | 89.47% | 86.77% | 86.77% | |
| EPS Diluted | 12.36% | 93.53% | 90.98% | 90.98% | |
| Normalized Diluted EPS | -0.04% | 89.47% | 86.77% | 86.77% | |
| Average Basic Shares Outstanding | 114.73% | 1,582.85% | 1,154.46% | 1,154.46% | |
| Average Diluted Shares Outstanding | 114.73% | 1,582.85% | 1,154.46% | 1,154.46% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |